PerpEquities

Equity · Financial services

CME Group (CME) perpetual futures

CME perpetual futures on 2 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade CMEUSDT.

CME Group Inc. operates international marketplaces for futures and options trading, offering clearing, market data, and risk management services to a global client base.

$308.42+1.4%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · MEXC (CMESTOCK/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

2/3 live markets
Venues
3
Live markets
2/3
24h volume
$297.4K
Open interest
$140.6KCoverage: 1/2 markets
Best liquidity
$2.4K
MEXC
Tightest spread
+20.4 bps
MEXC
Highest volume
$167.5K
MEXC
Settlement mix
USDT · 2/3
Perp/spot vol.
0.00x
Spot volume $637.8M
OI / float
0.00%
Float $108.9B
Spot performance
1D+1.38%
5D+1.79%
1M+17.15%
6M+6.19%
YTD+12.89%
1Y+15.09%

Venue matrix

3 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeCMESTOCK/USDTTrading$308.42-12.8% APR
-0.012% every 8h
+20.4 bps$2.4K$167.5K$140.6KUSDT20x
Helix (Injective)TradeCME/USDCTrading$308.41-24.1% APR
-0.00275% every 1h
--$129.9K-USDC12x
BingXTradeCMEUS-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 2 venues absorb $10k

Too thin: MEXC

No fresh book data: Helix (Injective)

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-23 · next report 2027-02-03 · Updated 271h ago
All financials →

Valuation & key figures

Market cap
$109.9B
Updated 271h ago
Revenue
$7B
Trailing 12 months
Revenue growth
+9%
Next fiscal year
Profit margin
+63.1%
P/E
24.9
Peer P/E 21.9
P/S
15.8
Peer P/E
21.9
Similar listed perps
Free cash flow
$3.3B
Trailing 12 months
Net income
$4.4B
Trailing 12 months
Revenue estimate
$7.1B
Next fiscal year
Earnings
2027-02-03
Revenue est. $1.8B · Updated 271h ago
Dividend
$1.3
2026-09-09
Revenue (TTM)$6.97B+9.0% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)65.7%+0.7 pp vs a year agoOperating income $4.58B
Net income (TTM)$4.4B+17.3% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$4.33B+6.1% vs a year agoCapex $93.7M
Diluted EPS (TTM)$12.19+18.1% vs a year agoSum of the last 4 quarters
Net cash-$1.1B-28.7% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-21): revenue beat by 1.3%, EPS beat by 1.0%Revenue $1.74B vs $1.71B expected (+1.3%); EPS $3.02 vs $2.99 (+1.0%).
  • Revenue growth accelerating: 13.0% year on yearQ3 '26 revenue $1.74B, against an average of 5.1% over the four quarters before.
  • Operating margin 65.7% (TTM), +0.7 pp on a year agoOperating income grew 10.1% while revenue grew 9.0%.
  • 20.7% of pre-tax profit is non-operatingPre-tax income $5.77B vs operating income $4.58B (TTM). Gains on equity stakes and other one-off items lift net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
clearing and transaction fees$1.38B+12.2%79.3%
MarketData$243M+20.0%14.0%
OtherRevenue$116M+8.3%6.7%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 256 lines CME Group Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-03
Revenue est. $1.8B · Updated 271h ago
Dividend
$1.3
2026-09-09

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202612.39$7.1B+9%10
FY 202713.20$7.5B+15%10
FY 202814.23$8B+22%4
FY 202915.43$8.5B+31%1
FY 203016.90$8.9B+36%1
Q1 20293.72$2.1B+10%3

Company events

6
2027-02-03EarningsActual - / Estimate 3.01-
2026-10-21Earnings · Before market openActual 3.02 / Estimate 2.99Beat
2026-09-09Dividend$1.3-
2026-07-22EarningsActual 2.99 / Estimate 2.91Beat
2026-06-09Dividend$1.3-
2026-04-22EarningsActual 3.36 / Estimate 3.34Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 2, 2026, 03:10 PM UTC

Company profile

Sector
Financial Services
Industry
Financial - Data & Stock Exchanges
Chief executive
Terrence A. Duffy
Employees
3,875
IPO date
Dec 6, 2002
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei0.6
Piotroski scorei6/9
Overall ratingiB+
Owner earningsi$1.09B$3.03 per share
ESG risk ratingiBIndustry rank: 11 out of 14

Rating factors

Return on equityi
5
Return on assetsi
4
Debt to equityi
4
Price to earningsi
1
Price to booki
1
Market cap history
$108.53B+13.3%Aug 26 – Oct 26
$94.77B$102.53B$110.29BHigh: $110.29B · 2026-10-26Low: $94.77B · 2026-09-28Latest: $108.53B · 2026-10-30Aug 26Sep 26Oct 26
Latest: $108.53B · 2026-10-30High: $110.29B · 2026-10-26Low: $94.77B · 2026-09-28
Largest fund holders
FundWeightShares held
VTI0.13%11.4M
VOO0.14%9.4M
IVV0.17%4.8M
1657.T0.13%4.8M
XSP.TO0.16%4.8M
XWD.TO0.12%4.8M
SPY0.16%4.4M
FXAIX0.14%4M
VTV0.36%3.4M
CDDRX1.44%2.6M
XLF1.33%2.4M
VIG0.42%2M

Analyst track record

How the analysts covering CME have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings99308
Analysts1722
Buy / hold / sell40 / 41 / 18113 / 155 / 40
Upgrades / downgrades / initiations5 / 2 / 210 / 12 / 5
Price targets hit / missed43 / 53 (45%)222 / 80 (74%)
Avg. return after a rating (TipRanks)+1.6%+14.6%
Best / worst call+41.8% / -19.2%+67.5% / -19.2%

After buy calls on this stock: median 21-day move +1.7% vs S&P 500 -0.8% (n = 116)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Christopher AllenKBW100% hit rate on this stock · 10 targets measuredBuytarget $330Oct 22, 2026
  2. Alex KrammUBS100% hit rate on this stock · 8 targets measuredHoldtarget $310Oct 22, 2026
  3. Michael CyprysMorgan Stanley100% hit rate on this stock · 8 targets measuredBuytarget $359Oct 22, 2026

Latest ratings

DateAnalystCallTarget
Oct 23, 2026Alexander BlosteinGoldman SachsSellMaintained$271
Oct 23, 2026Alexander BlosteinGoldman SachsSellMaintained$271
Oct 22, 2026Patrick MoleyPiper SandlerBuyReiterated$330
Oct 22, 2026Patrick MoleyPiper SandlerBuyReiterated$330
Oct 22, 2026Alex KrammUBSHoldMaintained$310
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$220$240$260$280$300$320Dec 25 · Buy 8 · Hold 4 · Sell 2Dec 25Jan 26 · Buy 7 · Hold 4 · Sell 2Feb 26 · Buy 7 · Hold 4 · Sell 2Feb 26Mar 26 · Buy 6 · Hold 5 · Sell 3Apr 26 · Buy 4 · Hold 5 · Sell 3Apr 26May 26 · Buy 4 · Hold 5 · Sell 3Jun 26 · Buy 5 · Hold 5 · Sell 3Jun 26Jul 26 · Buy 6 · Hold 5 · Sell 3Aug 26 · Buy 6 · Hold 5 · Sell 3Aug 26Sep 26 · Buy 6 · Hold 5 · Sell 3Oct 26 · Buy 9 · Hold 5 · Sell 2Oct 26Nov 26 · Buy 9 · Hold 5 · Sell 2Dec 25 · avg. target $292Jan 26 · avg. target $290Feb 26 · avg. target $299Mar 26 · avg. target $298Apr 26 · avg. target $304May 26 · avg. target $304Jun 26 · avg. target $298Jul 26 · avg. target $279Aug 26 · avg. target $278Sep 26 · avg. target $280Oct 26 · avg. target $309Nov 26 · avg. target $309Dec 25 · month-end close $273Jan 26 · month-end close $289Feb 26 · month-end close $320Mar 26 · month-end close $295Apr 26 · month-end close $288May 26 · month-end close $274Jun 26 · month-end close $221Jul 26 · month-end close $268Aug 26 · month-end close $286Sep 26 · month-end close $262Oct 26 · month-end close $303Nov 26 · month-end close $303

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Oct 30, 2026 · 99 ratings

Frequently asked questions

Where can I trade CME perpetual futures?

CME Group (CME) perpetual futures trade on 2 crypto venues, including MEXC, Helix (Injective). PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade CME around the clock?

Yes. Unlike the underlying stock, CME perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on CME perpetuals?

Right now the CME perp funding rate is -18.5% annualized (venue median), ranging from -24.1% to -12.8% across 2 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the CME perp price compare to the CME Group stock?

The venue-median CME perp mark is $308.4 versus a reference stock price of $308.4, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a CME perpetual future?

A CME perpetual is a derivative that tracks the price of CME Group with no expiry date. It lets you take long or short exposure to CME Group on crypto venues, around the clock.

What is CMEUSDT perpetual?

CMEUSDT is the symbol most crypto exchanges use for the CME Group perpetual settled in USDT (Tether). It tracks the CME share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

CME perpetuals · perpequities.comCME perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/cme-perp"><img src="https://perpequities.com/badge/cme-perp.svg" width="240" height="64" alt="CME perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of CME perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for CME — one email every Sunday.

Watchlist and alerts

Price and funding alerts for CME, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X